Huatai Securities has published a report predicting JD HEALTH (06618.HK) +0.320 (+0.658%) Short selling $77.28M; Ratio 154.143% 's 4Q25 revenue to have grown by 22.7% YoY on the strength of the heightened online penetration rate in the pharmaceutical category and supply chain advantages.The broker also expects JD HEALTH to have recorded non-IFRS operating profit of RMB260 million. In addition, the seasonal misalignment of the flu might provide short-term support for revenue growth in the last quarter.Throughout 2025, JD HEALTH is anticipated to have seen its revenue soar by 25% YoY to RMB72.7 billion and non-IFRS operating profit reach RMB4.11 billion. Huatai Securities has raised its 2025-27 non-IFRS net profit forecasts for the company by 11.6%/ 15.6%/ 22.4%.Huatai Securities has lifted its target price for JD HEALTH from HKD68.3 to HKD77.4 and kept the Buy rating unchanged.(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS Financial News